A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

March 9, 2015

Primary Completion Date

April 15, 2016

Study Completion Date

November 12, 2021

Conditions
Various Advanced Cancer
Interventions
DRUG

Nivolumab

Trial Locations (67)

1090

Local Institution - 0022, Brussels

2298

Local Institution - 0060, Waratah

2650

Local Institution - 0023, Edegem

3500

Local Institution - 0024, Hasselt

5112

Local Institution - 0070, Elizabeth Vale

10029

Local Institution - 0028, New York

18107

Local Institution, Rostock

20133

Local Institution - 0020, Milan

20246

Local Institution - 0042, Hamburg

27100

Local Institution - 0050, Pavia

28007

Local Institution - 0031, Madrid

28204

Local Institution - 0004, Charlotte

30607

University Cancer Blood Ctr, Athens

33521

Local Institution - 0009, Tampere

37404

Erlanger Oncology & Hematology - Univ. of TN, Chattanooga

41013

Local Institution - 0032, Seville

46202

Local Institution - 0030, Indianapolis

46804

Ft. Wayne Med Onco-Hema Inc, Fort Wayne

52100

Local Institution - 0017, Arezzo

55242

Local Institution - 0052, Iowa City

68130

GU Research Network, LLC, Omaha

69120

Local Institution - 0043, Heidelberg

70072

Crescent City Research Consortium, LLC, Marrero

72076

Local Institution - 0048, Tübingen

77030

Local Institution - 0001, Houston

80045

Local Institution - 0016, Aurora

80131

Local Institution - 0018, Napoli

81675

Local Institution - 0041, München

85054

Local Institution - 0013, Phoenix

91054

Local Institution - 0047, Erlangen

94115

Pacific Hematology Oncology Associates, San Francisco

97213

Local Institution - 0051, Portland

98101

Local Institution - 0036, Seattle

99028

Local Institution - 0049, Erfurt

1138431

Local Institution - 0085, Bunkyo-ku

1138603

Local Institution - 0073, Bunkyo-ku

1138655

Local Institution - 0077, Bunkyo-ku

1628666

Local Institution - 0075, Shinjuku-ku

2360004

Local Institution, Yokohama

3058576

Local Institution - 0081, Tsukuba

5898511

Local Institution - 0084, Osaka-Sayama-Shi

8608556

Local Institution - 0080, Kumamoto

9518520

Local Institution - 0076, Niigata

91010-3000

Local Institution - 0012, Duarte

48201-2014

Karmanos Cancer Institute, Detroit

19111-2412

Local Institution - 0029, Philadelphia

15212-0000

Local Institution - 0059, Pittsburgh

656 53

Local Institution - 0027, Brno

779 00

Local Institution - 0026, Olomouc

150 06

Local Institution, Prague

00029

Local Institution - 0010, Helsinki

07747

Local Institution - 0015, Jena

00149

Local Institution - 0021, Roma

0108543

Local Institution - 0074, Akita

036-8563

Local Institution - 0083, Hirosaki-shi

0208505

Local Institution - 0078, Morioka

602-8566

Local Institution - 0082, Kyoto

160-8582

Local Institution - 0086, Shinjuku-ku

80-219

Local Institution, Gdansk

31-531

Local Institution - 0046, Krakow

93-513

Local Institution - 0040, Lodz

71-730

Local Institution - 0056, Szczecin

50-556

Local Institution - 0038, Wroclaw

08916

Local Institution - 0035, Badalona-barcelona

08035

Local Institution - 0033, Barcelona

08908

Local Institution - 0034, Hospitalet de Llobregat - Barcelona

221 85

Local Institution - 0014, Lund

Sponsors
All Listed Sponsors
collaborator

Ono Pharmaceutical Co. Ltd

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY